NCT02858180View on ClinicalTrials.gov

Hepatitis C Virus(HCV) Heart and Lung Study

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

April 11, 2019

Study Completion Date

July 4, 2019

Conditions
Hepatitis C, ChronicHeart FailurePulmonary Disease, Chronic ObstructiveLung Diseases, Interstitial
Interventions
DRUG

Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)

1 pill once daily of SOF/LDV FDC

Trial Locations (4)

10032

Columbia University Medical Center, New York

27705

Duke University Medical Center - Dept of Gastroenterology, Durham

48377

Henry Ford Health System, Detroit

98104

Harborview Medical Center, Seattle

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Duke University

OTHER